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 Implication for health policy/practice/research/medical education:
Epidemiological studies have suggested a linkage between insulin resistance/type 2 diabetes and chronic HCV infection however 
molecular mechanism of this association is not well known. This review focuses on the recent advances in research about these 
possible pathways in order to bring out some common opinions on how to manage such patients with insulin resistance.
Context: HCV infection is strongly associated with development of insulin resistance and 
type-2 diabetes, however molecular mechanism of these associations is not known. The 
aim of this review was to conduct a comprehensive literature search to understand the 
nature of the association between hepatitis C virus (HCV) infection and insulin resist-
ance (IR). We also explored the role of HCV core protein and NS5a in modulating the 
course of the insulin-signaling pathway. 
Evidence Acquisitions:  We  searched  Directory  of  Open  Access  Journals  (DOAJ)  Google 
Scholar, Pubmed (NLM), LISTA (EBSCO), Web of Science (TS and PakMediNet). 
Results: Emerging evidence suggests an association between HCV infection and carotid/
coronary vascular disease. IR appears to be a dominant underlying cause of accelerated 
atherosclerosis in patients with chronic hepatitis C (CHC). HCV can induce IR directly 
through the stimulation of SOCS3 and PPA2, and both of these molecules have been 
shown  to  inhibit  interferon-α signaling. Improvement of insulin sensitivity may in-
crease the response rate to antiviral treatment and prevent IR complications, including 
vascular diseases. The results of several clinical trials that have used insulin sensitizers 
(metformin and PPAR-γ agonists) have been inconclusive. 
Conclusions: Beside the association between HCV and IR, the published data also have 
showed the possible association of HCV core and NS5A protein with IR.
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1. Context
Hepatitis  C  virus  (HCV)  infection  is  a  serious  health 
problem  affecting  over  130  million  people  worldwide 
(1). Approximately 85% of the HCV-infected population 
develops  severe  complications,  such  as  chronic  HCV 
(CHCV),  cirrhosis,  diabetes,  and  hepatocellular  carci-
nomas (2-7). CHCV is reported to be the major cause of 
50% to 76% of all liver cancers globally and also the rea-
son for two-third of all cases of liver transplantation in 
developed countries (8). It is recognized as a metabolic 
disease mainly because of its major role in the develop-
ment of insulin resistance (IR) and type 2 diabetes mel-12  Association of Hepatitis C Virus in Enhancing Insulin Resistance Badar S et al.
Hepat Mon. 2012:11-15
litus (T2DM). The precise nature of association of IR and 
CHCV is not completely understood yet; however, it is an 
established fact that HCV infection enhances IR, which in 
turn causes liver failure and the development of hepato-
cellular carcinomas (HCCs) (8) by affecting the response 
rate for antiviral therapy (9). Furthermore, old age, obe-
sity, severe liver fibrosis, and family history of diabetes 
are  the  key  risk  factors  for  diabetes  mellitus  (DM).  In 
non-diabetic HCV-infected patients, IR is associated with 
stages  of  liver  fibrosis  (10).  Several  HCV-induced  path-
ways lead to fibrosis, inflammation, steatosis, apoptosis, 
hepatocellular carcinoma, and insulin resistance (11-14). 
An insight into the mechanisms of liver failure, fibrosis, 
steatosis, and oxidative stress will help understand the 
association between HCV pathogenesis and IR (15). This 
review explores the role of CHCV in the development of 
IR and also analyzes the possible association of HCV core 
protein and NS5A protein with IR. 
2. Evidence Acquisition
Directory of Open Access Journals (DOAJ) Google Schol-
ar, Pubmed (NLM), LISTA (EBSCO), Web of Science (TS and 
PakMediNet) were searched with key words “Role of HCV 
in insulin resistance” “ Key observations relevant to insu-
lin resistance” , involvement of HCV in the development 
of insulin resistance” in recent 10 years. Thanks to Higher 
Education Commission (HEC) Government of Pakistan 
that we were able to obtain full articles on the reference 
lists from retrieved documents free of charges. As the in-
formation about this topic was rare, small clinical trials 
and case reports were also included. 
3. Results
We were able to found 70 research and review articles 
relevant to this topic directly or indirectly. From the in-
formation given in these papers, we drew out following 
aspects. 
3.1. Insulin 
Insulin, which is synthesized by the pancreatic β cells, is 
the most effective anabolic hormone. It is important for 
cell growth, cell differentiation, protein synthesis, and 
maintenance of glucose levels in the body (8). It regu-
lates blood glucose levels by inhibiting the production 
of liver glucose and by promoting the absorption of glu-
cose in muscle and adipose tissue (16). Insulin stimulates 
glucose transporter type 4 (GLUT4), which translocates 
glucose into the plasma membrane, thus increasing cell 
glucose uptake (8). It is also involved in lipid metabolism, 
suppressing lipolysis, and promoting lipid synthesis in 
liver, muscle, and adipose tissues (16). Insulin resistance 
develops when the concentration of insulin in blood is 
insufficient to efficiently regulate glucose uptake (17).
3.2. Insulin Signal Transduction
Insulin-signaling pathway begins when insulin binds 
to the extracellular α subunit of insulin receptor sub-
strate (IRS), which further phosphorylates the intracel-
lular tyrosine-kinase domain of the β subunit of the in-
sulin receptor. This phosphorylation produces docking 
sites for many other proteins having SH2 (Src homology 
2) domains like phosphatidylinositol 3-kinase (PI3k) (18, 
19). PI3k binds to IRS, which phosphorylates phosphati-
dylinositol 4,5-bisphosphate (PIP2) to phosphatidylinosi-
tol triphosphate (PIP3). Interaction of PIP3 with phospho-
sinositide-dependent kinase 1 (PDK1), in turn, activates 
protein kinase B (AKT/PKB) and protein kinase C (PKC) 
(20). Once activated, AKT/PKB decreases the blood glu-
cose levels mainly through 2 pathways. Firstly, by stimu-
lating the phosphorylation of glycogen synthase, which 
converts surplus glucose into glycogen. Secondly, by sup-
pressing glucose-6-phosphatase and phosphoenolpyru-
vate carboxykinase, which are involved in gluconeogen-
esis. Moreover, AKT is important for the localization of 
GLUT4 in the cell membrane and thus stimulates glucose 
uptake into skeletal muscle and adipose tissue (8). Insu-
lin resistance arises from the impairment of the above-
stated insulin-signaling pathway at multiple steps. One 
of the most important steps is the phosphorylation of 
key serine residues including Ser307, Ser318, Ser636, and 
Ser639 and not phosphorylation of the tyrosine residues 
for the inhibition of IRS (8). 
3.3. HCV Core Protein and IR
HCV core protein has been reported to induce overex-
pression of tumor necrosis factor-α (TNF-α) in the liver of 
transgenic mice and human hepatoma cell lines (21). TNF 
is  a  proinflammatory  cytokine  that  links  obesity  with 
IR (22). Over expression of TNF causes insulin resistance 
through  the  inhibition  of  PI3K-mediated  activation  of 
insulin receptor substrate 1 (IRS-1) and insulin recep-
tor substrate 2 (IRS-2), and tyrosine phosphorylation 
of the mitogen-activated protein kinases p42MAPK and 
p44MAPK. This phosphorylation leads to the impairment 
of glucose uptake in skeletal muscles (23) and also causes 
insulin resistance by inhibiting the IKK-β/NF-κB pathway 
(24). Expression of core protein in hepatocytes causes an 
increase in the phospholrylation of ISR-1 at Ser312, impairs 
the activation of AKT at the Thr308 phosphorylation site 
and also impairs insulin-stimulated glucose uptake (25). 
HCV core protein is also involved in the inhibition of ty-
rosine phosphorylation of IRS-1 and production of IRS-2 
through a PA28γ-dependent pathway (21) However, it ap-
pears implausible that the HCV core protein is localized 
and degraded in the nucleus through a PA28γ-dependent 
pathway as a major mechanism for insulin resistance. 
HCV core protein may play an important role in the regu-
lation of cellular inflammatory and immune responses 
through the activation of nuclear factor κ-light-chain 
enhancer of activated B cells (NF-κB) (26, 27). Activation 
of NF- κB is involved in the initiation of downstream pro-
duction  of  cytokine  (interleukin-6  [IL-6])  that  leads  to 
insulin resistance (28, 29). Increased production of TNF-α 
and suppressor of cytokine signaling-3 (SOCS-3) in HCV 13  Association of Hepatitis C Virus in Enhancing Insulin Resistance Badar S et al.
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infection promotes IR mainly through the inhibition of 
the insulin receptor and tyrosine phosphorylation of 
IRS-1 (30). The core protein causes improved production 
of SOCS-3, which leads to the degradation of IRS-1 and IRS-
2 (31). Although the effect of different genotypes of HCV 
on the insulin-signaling pathway is not yet clear, a sig-
nificant clinical association has been found between the 
genotypes and IR (8). Over expression of the core protein 
of genotype 3a and 1b in Huh7 cell line has no effect on 
the levels of IRS-2, but it reduces IRS-1 protein levels (32). 
In the case of the core protein of genotype 3a, degrada-
tion of IRS-1 is mediated by downregulation of the pro-
duction of peroxisome proliferator-activated receptor γ 
(PPARγ) and upregulation of SOCS-7 production; in con-
trast, genotype 1b core protein activates the mammalian 
target of rapamycin (mTOR) (32).
3.4. HCV NS5A and IR
The nonstructural protein 5A (NS5A) of HCV plays a sig-
nificant role in virus-driven IR. HCV NS5A and increased 
endoplasmic reticulum stress in HCV infection contrib-
utes to overexpression of protein phosphatase 2A (PP2A) 
(33, 34). Christein and colleagues reported that PP2A 
modulates insulin-signaling pathway by dephosphory-
lation of AKT, leading to IR in CHC patients (35). In their 
study, increased levels of PP2A were observed in liver bi-
opsies of HCV patients and also in HCV-protein-express-
ing livers of transgenic mice. In both the models, insulin 
signaling was inhibited through PP2A-catalyzed dephos-
phorylation of AKT (35). Moreover, PP2A can also impair 
interferon signaling, which is responsible for poor re-
sponse to interferon therapy for IR in HCV patients (36). 
3.5. Major Disorders Associated With HCV-Induced In-
sulin Resistance 
IR is mainly categorized into 2 types—HCV-induced IR 
and lifestyle-associated IR. Pathogenesis of HCV-induced 
insulin resistance is different from that of lifestyle-asso-
ciated IR (37). Cardiovascular diseases are the main cause 
of death of patients with lifestyle-associated IR (37, 38), 
while HCV-induced IR is responsible for many HCV-as-
sociated disorders (37) such as hepatic fibrosis, antiviral 
drug resistance, steatosis, and hepatocarcinogenesis.
3.6. Hepatic Fibrosis
IR plays a pivotal role in accelerating the severity of 
hepatic fibrosis in HCV-infected patients (31, 37, 39, 40), 
which is the main characteristic of the early stages of 
CHCV infection (10). It is because, IR stimulates the pro-
duction of free fatty acids and increases lipid deposition 
in the liver, which, in turn, enhances oxidative stress and 
consequently results in the development of liver fibrosis 
(41-43). Moreover, IR is also involved in the proliferation 
of hepatic stellate cells, which are the main site of depo-
sition of abnormal extracellular matrix in hepatic fibro-
sis (44, 45). 
3.7. Hepatic Steatosis
Liver steatosis is frequently observed in patients with 
CHCV infection (46). The rate of incidence of hepatic ste-
atosis in HCV-infected patients is approximately twice 
than the prevalence rate of steatosis in people with other 
common liver disorders such as hepatitis B (47, 48). One 
of the major factors responsible for the development of 
steatosis in HCV-infected patients is the production of 
triglycerides (49). The core protein of HCV induces ag-
gregation  of  triglycerides  (a  low-density  lipoprotein) 
through many mechanisms like activation of fatty acid 
synthase,  downregulation  of  microsomal  triglyceride 
transport protein, reduction of PPARγ, and upregulation 
of sterol regulatory element-binding protein-1c (49-51). 
HCV core protein is also responsible for the production 
of reactive oxygen species, which, in turn, trigger lipid 
peroxidation,  thus  resulting  in  severe  damage  to  the 
liver and ultimately to the development of steatosis (49, 
52). These findings show a tight association of HCV with 
hepatic  steatosis.  Moreover,  hepatic  insulin  resistance 
mediates  the  failure  of  the  insulin-signaling  pathway, 
leading to molecular and cellular changes that result in 
excess accumulation of triglycerides in the hepatocytes 
(53-55).
3.8. Hepatocarcinogenesis 
A  number  of  risk  factors,  such  as  male  sex,  age,  cir-
rhotic liver, and alcohol consumption are involved in 
the development of hepatocellular carcinoma (HCC) in 
HCV-infected patients (56-59). Recent studies show that 
IR is another key factor that plays a crucial role in the pro-
gression of liver cancer in HCV-infected patients (1, 60, 
61); however, the precise nature of the association is un-
known. IR is responsible for the excessive production of 
free fatty acids (62, 63), which causes increased liver adi-
posity, thus resulting in a reduction in the adiponectin 
levels and consequently the development of HCC (64). In 
addition, fatty acid deposition in hepatocytes causes oxi-
dative stress, which is another risk factor responsible for 
hepatocarcinogenesis (60, 61).
3.9. Antiviral-Drug Resistance
Resistance to antiviral treatment is another serious 
problem associated with HCV-induced IR (37, 65-67). Al-
though, the exact relationship between IR and poor re-
sponse to antiviral treatment is not clearly understood, 
IR is known to cause an accumulation of hepatic lipids 
important for HCV replication (62, 63). These droplets ac-
tivate viral replication and eventually lead to resistance 
to antiviral treatment not only in HCV genotype 1 but 
also in genotypes 2 and 3 (68). Moreover, SOCS-3 produc-
tion is upregulated by the HCV core protein, which is in-
volved in reducing interferon activity. (69, 70). 
4. Conclusions
In this review, we have summarized the association be-14  Association of Hepatitis C Virus in Enhancing Insulin Resistance Badar S et al.
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tween HCV and IR and also have analyzed the possible 
association of HCV core and NS5A protein with IR. IR is 
mainly  categorized  into  2  types—HCV-induced  IR  and 
lifestyle-associated IR. The pathogenesis of HCV-induced 
IR is different from that of lifestyle-associated IR. Car-
diovascular diseases are the main cause of death in the 
case of lifestyle-associated IR, and HCV-associated IR is 
responsible  for  many  HCV-related  conditions  such  as 
hepatic fibrosis, antiviral-drug resistance, steatosis, and 
hepatocarcinogenesis. IR arises from the impairment 
of the insulin-signaling pathway at multiple steps. Vari-
ous studies have reported that the core protein of HCV 
induces IR mainly by modulating the insulin-signaling 
pathway at the level of IRS. In the case of core proteins 
of genotype 3a, degradation of IRS-1 is mediated by the 
downregulation of PPARγ production and upregulation 
of SOCS-7 production; in contrast genotype 1b’s core pro-
tein activates mTOR. HCV NS5A and increased endoplas-
mic reticulum stress in HCV infection contributes to the 
overexpression of PP2A, which leads to the impairment 
of interferon signaling, and is thus responsible for poor 
response to interferon therapy for treating IR in HCV-in-
fected patients. Since the exact mechanisms of the mo-
lecular pathways of HCV-induced IR have not yet been 
understood, further research is required to determine 
how virus-induced IR can be managed.
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